Back to today’s briefing

Story perspectives

Cogent Biosciences Soars 137% After Historic GIST Trial Results

11/11/2025

24 4 Full Breakdown

Summary

Story summary

Cogent Biosciences (COGT) shares surged about 137% to a seven-year high after Phase 3 PEAK results for bezuclastinib in gastrointestinal stromal tumor.
Trial’s combination yielded median progression-free survival of 16.5 months versus 9.2 months with sunitinib alone.
CEO Andrew Robbins said the results are historic for GIST patients and could set a standard of care.
Cogent plans to submit a New Drug Application (NDA) in the first half of 2026.

1 of 1

Story summary

Cogent Biosciences (COGT) shares surged about 137% to a seven-year high after Phase 3 PEAK results for bezuclastinib in gastrointestinal stromal tumor.
Trial’s combination yielded median progression-free survival of 16.5 months versus 9.2 months with sunitinib alone.
CEO Andrew Robbins said the results are historic for GIST patients and could set a standard of care.
Cogent plans to submit a New Drug Application (NDA) in the first half of 2026.